Home > News

News

Shanks -v- Unilever18 January 2017In Shanks v Unilever [2017] EWCA Civ 2, the Court of Appeal dismissed Prof Shanks’ second tier appeal against the IPO’s rejection of his multi-million pound claim under s.40(1) of the Patents Act 1977 for inventor’s compensation against his former employer, Unilever, in respect of patents which he claimed to be of ‘outstanding benefit’ to […]
Teva, Accord, Lupin, and Generics UK trading as Mylan v Gilead Sciences Inc.13 January 2017Daniel Alexander QC and Lindsay Lane appeared for one claimant (Teva), Daniel Alexander QC and Jaani Riordan appeared for another claimant (Lupin), and James Whyte appeared for the defendant (Gilead), in these actions concerning Gilead’s Supplementary Protection Certificate (SPC) for an anti-retroviral drug combining tenofovir disoproxil and emtricibatine (marketed by Gilead as ‘Truvada’). The claimants […]
Fujifilm Kyowa Kirin Biologics Co. Limited v Abbvie Biotechnology Limited and Abbvie Limited [2017] EWCA Civ 112 January 2017Mark Chacksfield appeared on behalf of the Appellants Abbvie Biotechnology Limited (“Abbvie Bermuda”) and Abbvie Limited (“Abbvie UK” – together, “Abbvie”) in two linked appeals concerning FKB’s claims for declaratory relief in relation to its biosimilar products for the drug adalimumab (marketed by Abbvie as “Humira”). In related actions (“FKB1” and “FKB2”) FKB had sought […]
Fujifilm Kyowa Kirin Biologics Co. and Samsung Bioepis UK (2) Biogen IDEC -and- v AbbVie Biotechnology Ltd [2016] EWHC 3383 (Ch)29 December 2016Michael Tappin QC and Mark Chacksfield appeared on behalf of the Defendants, (together, “AbbVie”) in AbbVie’s application to strike out two linked actions brought on behalf of the Claimants, “FKB”, “SB” and “Biogen”. FKB/SB/Biogen sought declarations to the effect that biosimilar products for the antibody adalimumab (marketed by AbbVie as “Humira”) were obvious and/or anticipated […]
Novartis AG v Focus Pharmaceuticals UK Ltd21 December 2016Daniel Alexander QC and Henry Ward successfully represented the respondents, Focus and Actavis, in the first of two linked appeals concerning Novartis’ patent for a transdermal patch to deliver the drug Rivastigmine. Daniel Alexander QC and Mark Chacksfield represented the respondent, Teva, in the second appeal, on which the parties reached a settlement before the […]